NCT00792350View on ClinicalTrials.gov

INSIGHT - Post Marketing Surveillance

CompletedOBSERVATIONAL
Enrollment

791

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

October 31, 2013

Study Completion Date

April 30, 2014

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Treatment of Hepatocellular Carcinoma with Nexavar (HCC)

Trial Locations (2)

Unknown

Many Locations

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00792350 - INSIGHT - Post Marketing Surveillance | Biotech Hunter | Biotech Hunter